A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model

Julius W. Kim, Jason Michael Miska, Jacob S. Young, Aida Rashidi, J. Robert Kane, Wojciech K. Panek, Deepak Kanojia, Yu Han, Irina V Balyasnikova, Maciej S Lesniak*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic modality is common, has significant clinical benefit in animals, and its efficacy has recently been linked to an anti-tumor immune response that occurs following tumor antigen presentation. Here, we analyzed the adaptive immune system's response following viral infection by comparing replication-incompetent and replication-competent adenoviral vectors. Our findings suggest that cell death caused by replication-competent adenoviral vectors is required to induce a significant anti-tumor immune response and survival benefits in immunocompetent mice bearing intracranial glioma. We observed significant changes in the repertoire of immune cells in the brain and draining lymph nodes and significant recruitment of CD103+ dendritic cells (DCs) in response to oncolytic adenoviral therapy, suggesting the active role of the immune system in anti-tumor response. Our data suggest that the response to oncolytic virotherapy is accompanied by local and systemic immune responses and should be taken in consideration in the future design of the clinical studies evaluating oncolytic virotherapy in patients with glioblastoma multiforme (GBM).

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalMolecular Therapy - Oncolytics
Volume5
DOIs
StatePublished - Jun 1 2017

Fingerprint

Oncolytic Virotherapy
Glioma
Immune System
Neoplasms
Survival
Antigen Presentation
Adaptive Immunity
Neoplasm Antigens
Virus Diseases
Therapeutics
Glioblastoma
Adenoviridae
Dendritic Cells
Cell Death
Animal Models
Lymph Nodes
Brain

Keywords

  • immune-competent and immune-deficient murine glioma model
  • oncolytic virotherapy
  • replication-competent and replication-incompetent adenovirus
  • tumor-specific cytotoxic T and dendritic cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Kim, Julius W. ; Miska, Jason Michael ; Young, Jacob S. ; Rashidi, Aida ; Kane, J. Robert ; Panek, Wojciech K. ; Kanojia, Deepak ; Han, Yu ; Balyasnikova, Irina V ; Lesniak, Maciej S. / A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. In: Molecular Therapy - Oncolytics. 2017 ; Vol. 5. pp. 97-104.
@article{422be3cbe2794cd8901165fe341cb11b,
title = "A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model",
abstract = "Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic modality is common, has significant clinical benefit in animals, and its efficacy has recently been linked to an anti-tumor immune response that occurs following tumor antigen presentation. Here, we analyzed the adaptive immune system's response following viral infection by comparing replication-incompetent and replication-competent adenoviral vectors. Our findings suggest that cell death caused by replication-competent adenoviral vectors is required to induce a significant anti-tumor immune response and survival benefits in immunocompetent mice bearing intracranial glioma. We observed significant changes in the repertoire of immune cells in the brain and draining lymph nodes and significant recruitment of CD103+ dendritic cells (DCs) in response to oncolytic adenoviral therapy, suggesting the active role of the immune system in anti-tumor response. Our data suggest that the response to oncolytic virotherapy is accompanied by local and systemic immune responses and should be taken in consideration in the future design of the clinical studies evaluating oncolytic virotherapy in patients with glioblastoma multiforme (GBM).",
keywords = "immune-competent and immune-deficient murine glioma model, oncolytic virotherapy, replication-competent and replication-incompetent adenovirus, tumor-specific cytotoxic T and dendritic cells",
author = "Kim, {Julius W.} and Miska, {Jason Michael} and Young, {Jacob S.} and Aida Rashidi and Kane, {J. Robert} and Panek, {Wojciech K.} and Deepak Kanojia and Yu Han and Balyasnikova, {Irina V} and Lesniak, {Maciej S}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.omto.2017.05.001",
language = "English (US)",
volume = "5",
pages = "97--104",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. / Kim, Julius W.; Miska, Jason Michael; Young, Jacob S.; Rashidi, Aida; Kane, J. Robert; Panek, Wojciech K.; Kanojia, Deepak; Han, Yu; Balyasnikova, Irina V; Lesniak, Maciej S.

In: Molecular Therapy - Oncolytics, Vol. 5, 01.06.2017, p. 97-104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model

AU - Kim, Julius W.

AU - Miska, Jason Michael

AU - Young, Jacob S.

AU - Rashidi, Aida

AU - Kane, J. Robert

AU - Panek, Wojciech K.

AU - Kanojia, Deepak

AU - Han, Yu

AU - Balyasnikova, Irina V

AU - Lesniak, Maciej S

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic modality is common, has significant clinical benefit in animals, and its efficacy has recently been linked to an anti-tumor immune response that occurs following tumor antigen presentation. Here, we analyzed the adaptive immune system's response following viral infection by comparing replication-incompetent and replication-competent adenoviral vectors. Our findings suggest that cell death caused by replication-competent adenoviral vectors is required to induce a significant anti-tumor immune response and survival benefits in immunocompetent mice bearing intracranial glioma. We observed significant changes in the repertoire of immune cells in the brain and draining lymph nodes and significant recruitment of CD103+ dendritic cells (DCs) in response to oncolytic adenoviral therapy, suggesting the active role of the immune system in anti-tumor response. Our data suggest that the response to oncolytic virotherapy is accompanied by local and systemic immune responses and should be taken in consideration in the future design of the clinical studies evaluating oncolytic virotherapy in patients with glioblastoma multiforme (GBM).

AB - Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer. The use of an adenovirus vector for this therapeutic modality is common, has significant clinical benefit in animals, and its efficacy has recently been linked to an anti-tumor immune response that occurs following tumor antigen presentation. Here, we analyzed the adaptive immune system's response following viral infection by comparing replication-incompetent and replication-competent adenoviral vectors. Our findings suggest that cell death caused by replication-competent adenoviral vectors is required to induce a significant anti-tumor immune response and survival benefits in immunocompetent mice bearing intracranial glioma. We observed significant changes in the repertoire of immune cells in the brain and draining lymph nodes and significant recruitment of CD103+ dendritic cells (DCs) in response to oncolytic adenoviral therapy, suggesting the active role of the immune system in anti-tumor response. Our data suggest that the response to oncolytic virotherapy is accompanied by local and systemic immune responses and should be taken in consideration in the future design of the clinical studies evaluating oncolytic virotherapy in patients with glioblastoma multiforme (GBM).

KW - immune-competent and immune-deficient murine glioma model

KW - oncolytic virotherapy

KW - replication-competent and replication-incompetent adenovirus

KW - tumor-specific cytotoxic T and dendritic cells

UR - http://www.scopus.com/inward/record.url?scp=85020708999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020708999&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2017.05.001

DO - 10.1016/j.omto.2017.05.001

M3 - Article

VL - 5

SP - 97

EP - 104

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -